Date	Price Target	Rating	Analyst
9/25/2025	$456.00	Market Perform → Outperform	Leerink Partners
9/3/2025		Mkt Perform	Raymond James
8/6/2025	$460.00	Equal Weight → Overweight	Wells Fargo
5/7/2025		Outperform → Peer Perform	Wolfe Research
5/6/2025	$503.00	Outperform → Market Perform	Leerink Partners
4/22/2025	$535.00	Overweight	Cantor Fitzgerald
2/12/2025	$408.00 → $424.00	Sell → Hold	Canaccord Genuity
2/11/2025		Sell → Hold	Canaccord Genuity

More analyst ratings

FDA Approval for TRIKAFTA issued to VERTEX PHARMS INC

4/27/23 10:43:08 AM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRTX alert in real time by email

New Drug Application (NDA): 217660
Company: VERTEX PHARMS INC

Products on NDA 217660

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
TRIKAFTA	ELEXACAFTOR;TEZACAFTOR;IVACAFTOR;IVACAFTOR	50MG;25MG;37.5MG;75MG	GRANULES;ORAL	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217660

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
04/26/2023	ORIG-1	Approval	Type 3 - New Dosage Form	PRIORITY; Orphan		Label is not available on this site.

Get the next $VRTX alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$VRTX

Date	Price Target	Rating	Analyst
9/25/2025	$456.00	Market Perform → Outperform	Leerink Partners
9/3/2025		Mkt Perform	Raymond James
8/6/2025	$460.00	Equal Weight → Overweight	Wells Fargo
5/7/2025		Outperform → Peer Perform	Wolfe Research
5/6/2025	$503.00	Outperform → Market Perform	Leerink Partners
4/22/2025	$535.00	Overweight	Cantor Fitzgerald
2/12/2025	$408.00 → $424.00	Sell → Hold	Canaccord Genuity
2/11/2025		Sell → Hold	Canaccord Genuity

More analyst ratings

$VRTX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

View All

January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain. Journavx is the first dr

1/30/25 5:46:14 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

12/8/23 11:12:21 AM ET

$BLUE

$VRTX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

8/4/23 4:36:00 AM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

$VRTX
Press Releases

Fastest customizable press release news feed in the world

View All

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year; full enrollment completed for Phase 3 RAINIER trial in IgA nephropathy - - Povetacicept in primary membranous nephropathy granted Fast Track Designation by the U.S. Food and Drug Administration and Phase 2/3 pivotal trial initiated - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX

11/8/25 5:15:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex Reports Third Quarter 2025 Financial Results

— Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion — — R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete; on track to submit first module of povetacicept IgAN BLA to FDA by end of 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance. "Vertex delivered str

11/3/25 4:02:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The

10/27/25 4:00:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

$VRTX
Leadership Updates

Live Leadership Updates

View All

Vertex Appoints Nancy Thornberry to its Board of Directors

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

12/5/23 4:01:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex Appoints Michel Lagarde to its Board of Directors

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

10/5/23 8:00:00 AM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

8/29/23 9:00:00 AM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

$VRTX
Financials

Live finance-specific insights

View All

Vertex Reports Third Quarter 2025 Financial Results

11/3/25 4:02:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived w

10/6/25 4:00:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Vertex Reports Second Quarter 2025 Financial Results

— Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN and pMN, and inaxaplin in AMKD — — David Altshuler, M.D., PhD., Chief Scientific Officer (CSO), announces intent to retire August 1, 2026; as part of planned transition, Mark Bunnage, D.Phil., SVP of Global Research, to assume role of CSO effective February 1, 2026 — Vertex Pharmaceuticals Incor

8/4/25 4:01:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

FDA Approval for TRIKAFTA issued to VERTEX PHARMS INC

Products on NDA 217660

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217660

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VRTX

FDA Approval for TRIKAFTA issued to VERTEX PHARMS INC

Products on NDA 217660

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217660

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VRTX

$VRTX SEC Filings

SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

$VRTX FDA approvals

January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

$VRTX Press Releases

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vertex Reports Third Quarter 2025 Financial Results

Vertex to Participate in the UBS Global Healthcare Conference on November 11

$VRTX Analyst Ratings

Vertex Pharma upgraded by Leerink Partners with a new price target

Raymond James initiated coverage on Vertex Pharma

Vertex Pharma upgraded by Wells Fargo with a new price target

$VRTX Insider Trading

SEC Form 4 filed by Director Upadhyay Suketu

SEC Form 4 filed by Director Sachs Bruce I

EVP and Chief Legal Officer Biller Jonathan covered exercise/tax liability with 1,259 shares and sold $280,522 worth of shares (694 units at $404.21), decreasing direct ownership by 11% to 15,653 units (SEC Form 4)

$VRTX Insider Purchases

CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

$VRTX Leadership Updates

Vertex Appoints Nancy Thornberry to its Board of Directors

Vertex Appoints Michel Lagarde to its Board of Directors

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

$VRTX Financials

Vertex Reports Third Quarter 2025 Financial Results

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Vertex Reports Second Quarter 2025 Financial Results

$VRTX Large Ownership Changes

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

Recent Analyst Ratings for
$VRTX

Recent Analyst Ratings for
$VRTX

$VRTX
SEC Filings

$VRTX
FDA approvals

$VRTX
Press Releases

$VRTX
Analyst Ratings

$VRTX
Insider Trading

$VRTX
Insider Purchases

$VRTX
Leadership Updates

$VRTX
Financials

$VRTX
Large Ownership Changes